Key points from article :
Integrated Biosciences, a Silicon Valley biotech company, has secured $17.2 million in seed funding to advance the development of drugs for age-related diseases. The funding, led by Sutter Hill Ventures, will support the company’s efforts to create therapeutics that target cellular stress responses associated with conditions like neurodegeneration, cancer, diabetes, and osteoarthritis. These cellular processes are often disrupted by ageing, and Integrated Bio aims to modulate them using small-molecule drugs, promoting healthier ageing.
Founded in 2022, Integrated Bio combines synthetic biology and artificial intelligence (AI) to accelerate drug discovery. The company uses machine learning to analyse how cells respond to stress and identify new drug candidates more efficiently than traditional methods. Their approach has already led to the AI-driven discovery of a new class of antibiotics. With this new capital, the company plans to scale its platform and expand its preclinical drug pipeline.
Integrated Bio’s leadership team, including co-founders Dr. Felix Wong and Dr. Max Wilson, believes their innovative strategy will significantly speed up drug development and make age-related diseases more treatable. The company’s diversified approach involves developing multiple drug candidates simultaneously, potentially advancing them in-house or through partnerships. The scientific advisory board, featuring experts like MIT's Prof. James J. Collins and Nobel laureate Sir David W.C. MacMillan, strengthens their commitment to revolutionizing drug discovery and longevity therapeutics.
